申请人:Glaxo Group Limited
公开号:US04959381A1
公开(公告)日:1990-09-25
The present invention provides compounds of the general formula (I) ##STR1## wherein X represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain, and Y represents a bond, or a C.sub.1-4 alkylene, C.sub.2-4 alkenylene or C.sub.2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8; R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group, with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and Ar represents a pyridyl group optionally substituted by one or two substituents selected from halogen atoms or hydroxy, C.sub.1-3 alkyl and C.sub.1-3 alkoxy groups, or Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups hydroxy, hydroxyC.sub.1-3 alkyl, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, --NR.sup.3 R.sup.4 and --NR.sup.5 COR.sup.6, or Ar is a phenyl group substituted by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O--; where R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- and --S-- or a group --NH-- or --N(CH.sub.3)--; R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group; R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or --NR.sup.3 R.sup.4 group; p is an integer 1 or 2; and physiologically acceptable salts and solvates (e.g. hydrates) thereof. The compounds have a stimulant action at .beta.-adreno receptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.
本发明提供了通式(I)的化合物:其中X代表键或C.sub.1-6烷基,C.sub.2-6烯基或C.sub.2-6炔基链,Y代表键或C.sub.1-4烷基,C.sub.2-4烯基或C.sub.2-4炔基链,但X和Y中碳原子的总数不超过8;R.sup.1和R.sup.2分别代表氢原子或C.sub.1-3烷基,但R.sup.1和R.sup.2中碳原子的总数不超过4;Ar代表吡啶基,可选地被卤素原子或羟基,C.sub.1-3烷基和C.sub.1-3烷氧基等基团取代,或Ar代表苯基,可选地被卤素原子或羟基,羟基C.sub.1-3烷基,C.sub.1-3烷基,C.sub.1-3烷氧基,--NR.sup.3 R.sup.4和--NR.sup.5 COR.sup.6等基团取代,或Ar是被式--O(CH.sub.2).sub.p O--的烷二醚基团取代的苯基;其中R.sup.3和R.sup.4分别代表氢原子或C.sub.1-4烷基,或--NR.sup.3 R.sup.4形成饱和杂环氨基,该氨基具有5-7个环成员,并且可选地在环中含有一个或多个选自--O--和--S--或--NH--或--N(CH.sub.3)--的原子;R.sup.5代表氢原子或C.sub.1-4烷基;R.sup.6代表氢原子或C.sub.1-4烷基,C.sub.1-4烷氧基,苯基或--NR.sup.3 R.sup.4基团;p是整数1或2;以及其生理上可接受的盐和溶剂(例如水合物)。这些化合物在β-肾上腺素受体上具有兴奋作用,并可用于治疗与可逆性气道阻塞相关的疾病,例如哮喘和慢性支气管炎。